---
title: "Endocrine Society Roadmap: Research Priorities and Gaps in Obesity Science"
id: "endocrine-news-0-endocrine-society-scientific-statement-provides-research-roadmap-for-what-s"
canonical_url: "https://medichelpline.com/clinical-feed/endocrine-news-0-endocrine-society-scientific-statement-provides-research-roadmap-for-what-s"
content_type: "clinical_feed_article"
specialty: "Endocrinology"
source_name: "Endocrine News"
source_url: "https://endocrinenews.endocrine.org/endocrine-society-scientific-statement-provides-research-roadmap-for-whats-next-in-obesity-science/"
published_at: "2026-09-09T18:01:09.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Endocrine Society Roadmap: Research Priorities and Gaps in Obesity Science
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/endocrine-news-0-endocrine-society-scientific-statement-provides-research-roadmap-for-what-s
- **Specialty:** [Endocrinology](https://medichelpline.com/clinical-feed/endocrinology.md)
- **Primary Source:** Endocrine News
- **Source URL:** [Original Journal Publication](https://endocrinenews.endocrine.org/endocrine-society-scientific-statement-provides-research-roadmap-for-whats-next-in-obesity-science/)
- **Published At:** 2026-09-09T18:01:09.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The Endocrine Society released a Scientific Statement summarizing current knowledge on **obesity** and outlining a research roadmap to address key gaps in understanding and treatment. - The Statement emphasizes that obesity is a complex, chronic disease driven by biology, genetics, metabolism, brain function, and environment, not simply willpower. - The article notes obesity affects over 40% of American adults and imposes more than $173 billion annually in U.S. obesity-related medical costs. - New GLP-1–based therapies such as **semaglutide** and **tirzepatide** have transformed treatment and are being used to address obesity and related comorbidities, including cardiovascular disease, sleep apnea, kidney and liver disease. - Important safety and long-term questions remain about GLP-1s: direct medication effects, consequences of rapid weight loss, long-term risks and outcomes. - Obesity requires long-term management; stopping treatment after goal weight commonly leads to weight regain and worsening of metabolic parameters. - Evidence suggests many patients can maintain weight loss when transitioned to lower-dose or different therapies, but more data are needed. - The Statement identifies six priority research areas: fat regulation and storage, interindividual heterogeneity in obesity, redefinition of treatment targets beyond weight, longitudinal responses to anti-obesity drugs, health outcomes with these medications, and long-term safety. - The authors call for larger, longer, more diverse studies and greater use of real-world data to better define treatment precision, clinical outcomes, and safe use of emerging therapies. - The Statement was developed by an Endocrine Society Task Force and published in Endocrine Reviews as part of the Society’s Center on Obesity initiative.
## Clinical Analysis & Structured Key Points
[Skip to content](https://endocrinenews.endocrine.org/endocrine-society-scientific-statement-provides-research-roadmap-for-whats-next-in-obesity-science/#wp--skip-link--target) [Endocrine News](https://endocrinenews.endocrine.org) [![Endocrine News](https://endocrinenews.endocrine.org/wp-content/uploads/es-reversed.svg)](https://endocrinenews.endocrine.org/) * [Topics](https://endocrinenews.endocrine.org/category/health-topic/diabetes/) * [Diabetes](https://endocrinenews.endocrine.org/category/health-topic/diabetes/) * [Obesity](https://endocrinenews.endocrine.org/category/health-topic/obesity/) * [Adrenal](https://endocrinenews.endocrine.org/category/health-topic/adrenal/) * [Bone and Mineral](https://endocrinenews.endocrine.org/category/health-topic/bone-and-mineral/) * [Cardiometabolic](https://endocrinenews.endocrine.org/category/health-topic/cardiometabolic/) * [Endocrine Disruptors](https://endocrinenews.endocrine.org/category/health-topic/endocrine-disruptors/) * [Head Glands](https://endocrinenews.endocrine.org/category/health-topic/head-glands/) * [Kidney Issues](https://endocrinenews.endocrine.org/category/health-topic/kidney-issues/) * [Neoplasia and Cancer](https://endocrinenews.endocrine.org/category/health-topic/neoplasia-and-cancer/) * [Pancreas](https://endocrinenews.endocrine.org/category/health-topic/pancreas/) * [Reproductive Issues](https://endocrinenews.endocrine.org/category/health-topic/reproductive-issues/) * [Thyroid](https://endocrinenews.endocrine.org/category/health-topic/thyroid/) * [Pediatric Health](https://endocrinenews.endocrine.org/category/patient-populations/pediatric-health/) * [Men’s Health](https://endocrinenews.endocrine.org/category/patient-populations/mens-health/) * [Women’s Health](https://endocrinenews.endocrine.org/category/patient-populations/womens-health/) * [Why Endocrinology?](https://endocrinenews.endocrine.org/category/why-endocrinology/) * [Practice](https://endocrinenews.endocrine.org/category/practice/) * [Your Practice](https://endocrinenews.endocrine.org/category/practice/your-practice/) * [Your Patients](https://endocrinenews.endocrine.org/category/practice/your-patients/) * [Product / Technology](https://endocrinenews.endocrine.org/category/practice/product-technology/) * [Endocrinology Workforce](https://endocrinenews.endocrine.org/category/endocrinology-workforce/) * [Lab Notes](https://endocrinenews.endocrine.org/category/lab-notes/) * [Q&A](https://endocrinenews.endocrine.org/category/lab-notes/q-a/) * [Your Laboratory](https://endocrinenews.endocrine.org/category/your-laboratory/) * [Products and Technological Advancements in Endocrinology](https://endocrinenews.endocrine.org/category/lab-notes/products-technology/) * [Advocacy](https://endocrinenews.endocrine.org/category/advocacy/) * [Clinical](https://endocrinenews.endocrine.org/category/advocacy/clinical/) * [Research](https://endocrinenews.endocrine.org/category/advocacy/research/) * [InTouch](https://endocrinenews.endocrine.org/intouch/) * [Member News](https://endocrinenews.endocrine.org/category/in-touch/member-news-in-touch/) * [Society News](https://endocrinenews.endocrine.org/category/in-touch/society-news/) * [Podcast](https://www.endocrine.org/podcast) * [Current Issue Download](https://endocrinenews.endocrine.org/magazine/current-issue/) * [My Profile](https://ams.endocrine.org/eweb/) * [Log In](https://endocrinenews.endocrine.org/auth/login) * [Log Out](https://endocrinenews.endocrine.org/auth/logout) * [Topics](https://endocrinenews.endocrine.org/category/health-topic/diabetes/) * [Diabetes](https://endocrinenews.endocrine.org/category/health-topic/diabetes/) * [Obesity](https://endocrinenews.endocrine.org/category/health-topic/obesity/) * [Adrenal](https://endocrinenews.endocrine.org/category/health-topic/adrenal/) * [Bone and Mineral](https://endocrinenews.endocrine.org/category/health-topic/bone-and-mineral/) * [Cardiometabolic](https://endocrinenews.endocrine.org/category/health-topic/cardiometabolic/) * [Endocrine Disruptors](https://endocrinenews.endocrine.org/category/health-topic/endocrine-disruptors/) * [Head Glands](https://endocrinenews.endocrine.org/category/health-topic/head-glands/) * [Kidney Issues](https://endocrinenews.endocrine.org/category/health-topic/kidney-issues/) * [Neoplasia and Cancer](https://endocrinenews.endocrine.org/category/health-topic/neoplasia-and-cancer/) * [Pancreas](https://endocrinenews.endocrine.org/category/health-topic/pancreas/) * [Reproductive Issues](https://endocrinenews.endocrine.org/category/health-topic/reproductive-issues/) * [Thyroid](https://endocrinenews.endocrine.org/category/health-topic/thyroid/) * [Pediatric Health](https://endocrinenews.endocrine.org/category/patient-populations/pediatric-health/) * [Men’s Health](https://endocrinenews.endocrine.org/category/patient-populations/mens-health/) * [Women’s Health](https://endocrinenews.endocrine.org/category/patient-populations/womens-health/) * [Why Endocrinology?](https://endocrinenews.endocrine.org/category/why-endocrinology/) * [Practice](https://endocrinenews.endocrine.org/category/practice/) * [Your Practice](https://endocrinenews.endocrine.org/category/practice/your-practice/) * [Your Patients](https://endocrinenews.endocrine.org/category/practice/your-patients/) * [Product / Technology](https://endocrinenews.endocrine.org/category/practice/product-technology/) * [Endocrinology Workforce](https://endocrinenews.endocrine.org/category/endocrinology-workforce/) * [Lab Notes](https://endocrinenews.endocrine.org/category/lab-notes/) * [Q&A](https://endocrinenews.endocrine.org/category/lab-notes/q-a/) * [Your Laboratory](https://endocrinenews.endocrine.org/category/your-laboratory/) * [Products and Technological Advancements in Endocrinology](https://endocrinenews.endocrine.org/category/lab-notes/products-technology/) * [Advocacy](https://endocrinenews.endocrine.org/category/advocacy/) * [Clinical](https://endocrinenews.endocrine.org/category/advocacy/clinical/) * [Research](https://endocrinenews.endocrine.org/category/advocacy/research/) * [InTouch](https://endocrinenews.endocrine.org/intouch/) * [Member News](https://endocrinenews.endocrine.org/category/in-touch/member-news-in-touch/) * [Society News](https://endocrinenews.endocrine.org/category/in-touch/society-news/) * [Podcast](https://www.endocrine.org/podcast) * [Current Issue Download](https://endocrinenews.endocrine.org/magazine/current-issue/) * [My Profile](https://ams.endocrine.org/eweb/) * [Log In](https://endocrinenews.endocrine.org/auth/login) * [Log Out](https://endocrinenews.endocrine.org/auth/logout) Search Search [Current Issue Download](https://endocrinenews.endocrine.org/magazine-issues/august-2026/) [Login](https://endocrinenews.endocrine.org/auth/login/?redirect=https://endocrinenews.endocrine.org/endocrine-society-scientific-statement-provides-research-roadmap-for-whats-next-in-obesity-science/) ![](https://endocrinenews.endocrine.org/wp-content/themes/mg-starter/assets/images/Endocrine_News_standard_logo.svg) * * * # Endocrine Society Scientific Statement Provides Research Roadmap for What’s Next in Obesity Science September 9, 2026 Print this article Share this article A new Scientific Statement released today by the Endocrine Society highlights the benefits of obesity treatment beyond weight loss, including improvements in overall health and reducing the risk of conditions such as heart disease, sleep apnea and liver disease. Obesity is a complex, chronic disease influenced by biology, genetics, metabolism, the brain, and environmental factors — not simply a matter of willpower. The disease affects **[over 40% of American adults](https://zwly9k6z.r.us-east-1.awstrack.me/L0/https:%2F%2Fwww.endocrine.org%2F-%2Fmedia%2Fendocrine%2Ffiles%2Fadvocacy%2Fpdfs%2Fobesity-playbook-july-2025-final.pdf/1/010001a086af0ba0-d76dba2a-9b7d-46b8-9685-e0368a79198d-000000/DbHPL7_fefEemj8yWPHSg6AhgvU=473) **and costs over $173 billion annually in U.S. obesity-related medical care costs. “This Statement highlights major advances in obesity science and outlines areas of research needed to improve our understanding of the disease, optimize treatment, personalize care and improve long-term health outcomes for people living with obesity,” said Daniel J. Drucker, MD, of Mount Sinai Hospital in Toronto, Ontario, Canada, lead author of the Scientific Statement writing group. “The rapid adoption of highly effective obesity medications has changed the treatment landscape, but important questions remain about their long-term use, individualized treatment strategies, side effects and the best ways to measure treatment outcomes.” The statement outlines what researchers know, what they still need to learn and where future research on obesity should focus. Semaglutide, tirzepatide, and other GLP-1 based therapies have transformed obesity treatment and helped us better understand the disease. They are now being used not only for treatment of overweight and obesity, but also for improving comorbidities including heart disease, sleep apnea, kidney and liver disease, and being investigated for other diseases such as cancer, substance use disorders, arthritis and infertility. > “The rapid adoption of highly effective obesity medications has changed the treatment landscape, but important questions remain about their long-term use, individualized treatment strategies, side effects and the best ways to measure treatment outcomes.” > Daniel J. Drucker, MD, Mount Sinai Hospital in Toronto, Ontario, Canada If left untreated, obesity can cause poor metabolic and mental health, and a reduced ability to perform the basic physical tasks and movements needed for everyday living. However, there are safety considerations with GLP-1s including the medications’ direct effects, consequences of rapid weight loss, and areas where long-term risks and outcomes remain uncertain. Research supports that obesity is a chronic disease that requires long-term treatment. People with obesity who stop treatment after reaching their goal weight often gain it back and experience worsening of other health issues such as blood pressure, cholesterol and blood sugar levels. Studies show that people can maintain much of their weight loss when transitioning to lower-dose therapies or different medications after initial treatment. The Statement identifies these key questions and priorities for future research on obesity: * How the body regulates and stores fat * Why obesity manifests differently in individuals and how this affects treatment * Redefining treatment targets beyond weight loss * How the body responds to anti-obesity medications over time * Health outcomes with anti-obesity medications * How safe new anti-obesity medications are for long-term use “Advancing research across these six priority areas will help transform obesity care by deepening our understanding of disease biology, improving treatment precision, defining meaningful clinical outcomes and optimizing the safe and effective use of emerging therapies,” Drucker said. “We need larger, longer, and more diverse studies, as well as greater use of real-world data to understand treatment outcomes.” The Endocrine Society develops [Scientific Statements](https://zwly9k6z.r.us-east-1.awstrack.me/L0/https:%2F%2Fwww.endocrine.org%2Fadvancing-research%2Fscientific-statements/1/010001a086af0ba0-d76dba2a-9b7d-46b8-9685-e0368a79198d-000000/OiVsScheKWcqfRBvOLJn1UAFnS0=473) to explore the scientific basis of hormone-related conditions and diseases, discuss how this knowledge can be applied in practice and identify areas that require additional research. Topics are selected on the basis of their emerging scientific impact. Scientific Statements are developed by a Task Force of experts appointed by the Endocrine Society, with internal review by the relevant Society committees and expert external reviewers prior to a comment period open to all members of the Society. Other statement authors are Ania M. Jastreboff, Harlan M. Krumholz and Michelle Van Name of Yale University School of Medicine in New Haven, Conn.; Jamy D. Ard of Wake Forest University School of Medicine in Winston-Salem, N.C.; Kevin D. Hall of AstraZeneca Inc.; Lee M. Kaplan of Geisel School of Medicine at Dartmouth in Hanover, N.H.; and Donna H. Ryan of Louisiana State University in Baton Rouge, La. The statement, _“Obesity Science, Research Gaps, and Opportunities in the New Era of Obesity Medicines – an Endocrine Society Scientific Statement,”_ was published online in the Society’s journal _, Endocrine Reviews._ The Scientific Statement is part of the Society’s [**Center on Obesity**](https://zwly9k6z.r.us-east-1.awstrack.me/L0/https:%2F%2Fwww.endocrine.org%2Fcenter-on-obesity/1/010001a086af0ba0-d76dba2a-9b7d-46b8-9685-e0368a79198d-000000/uCk4o6wMows5FBSzPlcuiOEuUHE=473), a broader initiative to advance obesity research and care. * * * ## TOPICS IN THIS ARTICLE: [Obesity](https://endocrinenews.endocrine.org/category/health-topic/obesity/)[Society News](https://endocrinenews.endocrine.org/category/in-touch/society-news/) ←[VIDEO: AI Model Identifies Patients at Risk of Underdiagnosed Cause of High Blood Pressure](https://endocrinenews.endocrine.org/video-ai-model-identifies-patients-at-risk-of-underdiagnosed-cause-of-high-blood-pressure/) ## RELATED ARTICLES * ### [ Endocrine Society Applauds Introduction of Bipartisan Bill to Address Insulin Affordability in the House ](https://endocrinenews.endocrine.org/endocrine-society-applauds-introduction-of-bipartisan-bill-to-address-insulin-affordability-in-the-house/) September 3, 2026 * ![Where Disciplines Converge: Keystone and Society Partner on Scientific Meeting Series](https://endocrinenews.endocrine.org/wp-content/uploads/ENDO-2026-keystone-symposium-1024x768.jpg) ### [ Where Disciplines Converge: Keystone and Society Partner on Scientific Meeting Series ](https://endocrinenews.endocrine.org/where-disciplines-converge-keystone-and-society-partner-on-scientific-meeting-series/) August 20, 2026 * ![Looking Back: Unforgettable Moments from ENDOs Past](https://endocrinenews.endocrine.org/wp-content/uploads/ENDO-2022-all-sig-reception-scaled-1-1024x682.jpg) ### [ Looking Back: Unforgettable Moments from ENDOs Past ](https://endocrinenews.endocrine.org/looking-back-unforgettable-moments-from-endos-past/) July 2, 2026 * * * ADVERTISEMENT ![August 2026](https://endocrinenews.endocrine.org/wp-content/uploads/08.26_coverPROOF001-749x1024.jpg) [View Archives](https://endocrinenews.endocrine.org/magazine-issues/) ADVERTISEMENT ADVERTISEMENT ![](https://endocrinenews.endocrine.org/wp-content/themes/mg-starter/assets/images/scientists_optim-1024x569.jpg) ## Join the Global Movement Advancing Endocrine Science and Medicine Become a part of a community of 18,000-plus endocrine investigators and clinicians who conduct research and provide quality patient care in more than 100 countries. Advance your career and the field of endocrinology through our many educational, leadership and advocacy opportunities. [Join Today](https://www.endocrine.org/membership) [![](https://endocrinenews.endocrine.org/wp-content/themes/mg-starter/assets/images/Endocrine_Society_Logo.webp)](https://www.endocrine.org/) ![](https://endocrinenews.endocrine.org/wp-content/themes/mg-starter/assets/images/Endocrine_News_standard_logo.svg) [![](https://endocrinenews.endocrine.org/wp-content/themes/mg-starter/assets/images/facebook.svg)](http://www.facebook.com/pages/The-Endocrine-Society/93758955863)[![](https://endocrinenews.endocrine.org/wp-content/themes/mg-starter/assets/images/x.svg)](https://x.com/TheEndoSociety)[![](https://endocrinenews.endocrine.org/wp-content/themes/mg-starter/assets/images/linkedin.svg)](https://www.linkedin.com/company/the-endocrine-society/) ## Research * * * ### Health Topics [Adrenal](https://endocrinenews.endocrine.org/category/health-topic/adrenal/) [Bone and Mineral](https://endocrinenews.endocrine.org/category/health-topic/adrenal/) [Cardiometabolic](https://endocrinenews.endocrine.org/category/health-topic/cardiometabolic/) [Diabetes](https://endocrinenews.endocrine.org/category/health-topic/diabetes/) [Endocrine Disruptors](https://endocrinenews.endocrine.org/category/health-topic/endocrine-disruptors/) [Head Glands](https://endocrinenews.endocrine.org/category/health-topic/head-glands/) [Kidney Issues](https://endocrinenews.endocrine.org/category/health-topic/kidney-issues/) [Neoplasia and Cancer](https://endocrinenews.endocrine.org/category/health-topic/neoplasia-and-cancer/) [Obesity](https://endocrinenews.endocrine.org/category/health-topic/obesity/) [Pancreas](https://endocrinenews.endocrine.org/category/health-topic/pancreas/) [Reproductive Issues](https://endocrinenews.endocrine.org/category/health-topic/reproductive-issues/) [Thyroid](https://endocrinenews.endocrine.org/category/health-topic/thyroid/) [Transgender Health](https://endocrinenews.endocrine.org/category/health-topic/transgender-health/) ### Patient Populations [](https://endocrinenews.endocrine.org/category/health-topic/adrenal/)[Health Disparities](https://endocrinenews.endocrine.org/category/health-topic/bone-and-mineral/) [Men’s Health](https://endocrinenews.endocrine.org/category/patient-populations/mens-health/) [Pediatric Health](https://endocrinenews.endocrine.org/category/patient-populations/pediatric-health/) [Women’s Health](https://endocrinenews.endocrine.org/category/patient-populations/womens-health/) * [Topics](https://endocrinenews.endocrine.org/category/health-topic/diabetes/) * [Diabetes](https://endocrinenews.endocrine.org/category/health-topic/diabetes/) * [Obesity](https://endocrinenews.endocrine.org/category/health-topic/obesity/) * [Adrenal](https://endocrinenews.endocrine.org/category/health-topic/adrenal/) * [Bone and Mineral](https://endocrinenews.endocrine.org/category/health-topic/bone-and-mineral/) * [Cardiometabolic](https://endocrinenews.endocrine.org/category/health-topic/cardiometabolic/) * [Endocrine Disruptors](https://endocrinenews.endocrine.org/category/health-topic/endocrine-disruptors/) * [Head Glands](https://endocrinenews.endocrine.org/category/health-topic/head-glands/) * [Kidney Issues](https://endocrinenews.endocrine.org/category/health-topic/kidney-issues/) * [Neoplasia and Cancer](https://endocrinenews.endocrine.org/category/health-topic/neoplasia-and-cancer/) * [Pancreas](https://endocrinenews.endocrine.org/category/health-topic/pancreas/) * [Reproductive Issues](https://endocrinenews.endocrine.org/category/health-topic/reproductive-issues/) * [Thyroid](https://endocrinenews.endocrine.org/category/health-topic/thyroid/) * [Pediatric Health](https://endocrinenews.endocrine.org/category/patient-populations/pediatric-health/) * [Men’s Health](https://endocrinenews.endocrine.org/category/patient-populations/mens-health/) * [Women’s Health](https://endocrinenews.endocrine.org/category/patient-populations/womens-health/) * [Why Endocrinology?](https://endocrinenews.endocrine.org/category/why-endocrinology/) * [Practice](https://endocrinenews.endocrine.org/category/practice/) * [Your Practice](https://endocrinenews.endocrine.org/category/practice/your-practice/) * [Your Patients](https://endocrinenews.endocrine.org/category/practice/your-patients/) * [Product / Technology](https://endocrinenews.endocrine.org/category/practice/product-technology/) * [Endocrinology Workforce](https://endocrinenews.endocrine.org/category/endocrinology-workforce/) * [Lab Notes](https://endocrinenews.endocrine
## Related Clinical Research

- [GLP-1 receptor agonists and PMOS: evidence, mechanisms, and who may benefit](https://medichelpline.com/clinical-feed/medical-news-today-0-can-glp-1s-really-help-treat-pmos-experts-answer-3-key-questions.md)
- [Undiagnosed type 2 diabetes presenting as DKA with hypertriglyceridemia-induced acute pancreatitis](https://medichelpline.com/clinical-feed/cmaj-1-undiagnosed-type-2-diabetes-presenting-as-diabetic-ketoacidosis-with.md)
- [No Patient Left Behind: Expanding Semaglutide’s Reach](https://medichelpline.com/clinical-feed/endocrine-news-21-no-patient-left-behind-expanding-semaglutide-s-reach.md)
- [Beyond the Scale: What Else Glucagon-like Peptide-1 Receptor Agonists Can Do](https://medichelpline.com/clinical-feed/endocrine-news-34-beyond-the-scale-what-else-glucagon-like-peptide-1-receptor-agonists-can-do.md)
- [Orforglipron Added to Titrated Insulin Glargine Improves Glycemic Control and Weight in Type 2 Dia](https://medichelpline.com/clinical-feed/pubmed-42251769.md) (DOI: 10.1001/jama.2026.9512)

## Navigation
- [← Back to Endocrinology Feed](https://medichelpline.com/clinical-feed/endocrinology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.